NUVB

Insider Trades

Name	Value	Action	Price	Current Price
Mashal RobertDirector $4219 shares BuyOct 8, 2024 $2.20 --
Mashal RobertDirector $220k100k shares BuyOct 8, 2024 $2.20 --
Wang Junyuan JerryDirector, Officer: CEO, ANHEART THERAPEUTICS LTD. $163k56.4k shares SellNov 11, 2024 $2.89 --
Mashal RobertDirector $1.8k1.1k shares BuyApr 1, 2025 $1.67 --
Mashal RobertDirector $165k98.9k shares BuyApr 1, 2025 $1.67 --
Hung DavidDirector, 10 Percent Owner, Officer: PRESIDENT AND CEO $333k200k shares BuyApr 4, 2025 $1.66 --

News

fool.comVeteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentumfool.comJun 17

seekingalpha.comNuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Levelseekingalpha.comJun 15

seekingalpha.comNuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade)seekingalpha.comJun 8

prnewswire.comNuvation Bio to Present at the Jefferies Global Healthcare Conferenceprnewswire.comMay 27

prnewswire.comNuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meetingprnewswire.comMay 27

Trade NUVB

About Nuvation Bio Inc.

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

CEO: David T. Hung
IPO Date: Aug 26, 2020

Market Data

Open: $5.44
High: $5.58
Low: $5.33
Volume: 3.7M
Avg Volume: 4.1M
52W High: $9.75
52W Low: $1.81

Valuation

Market Cap: $1.9B
Enterprise Value: $1.8B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-174M
Revenue: $63M
Net Income: $-205M
Cash: $164M
Debt: $10M

Events

EarningsAug 6

EPS est. -0.15